A biomarker-selected single-arm trial [55] in KRAS-mutant NSCLC reported a 31% objective response rate with pelareorep plus chemotherapy, but without a control group, this serves mainly to show feasibility and some activity. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.